Exchange: NYSE·Updated 07:56 PM EDT

BMY News

News
all
press releases
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Zacks
More News
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Zacks
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Zacks
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
Zacks
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic...
Business Wire
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
Zacks
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
Zacks

Advertisement|Remove ads.